Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Pediatric neurology · Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS)

Understanding Your Child's NEDAMSS Diagnosis

At a Glance

NEDAMSS is an ultra-rare IRF2BPL-related condition in which children may lose developmental skills, speech, or coordination and develop abnormal movements or seizures. Care focuses on individualized monitoring, therapies, communication support, and seizure management.

Receiving a diagnosis of NEDAMSS (Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures) is often a moment of profound shock and confusion for families. For many parents, the diagnosis comes after months or years of searching for answers—a “diagnostic odyssey” that may have included several incorrect or inconclusive tests [1][2]. It is natural to feel overwhelmed by the rarity of this condition and the scientific complexity of the genetics involved.

What Is NEDAMSS?

NEDAMSS is an ultra-rare genetic condition caused by changes (variants) in the IRF2BPL gene [3]. The name is an acronym that describes the most common clinical features seen in children with the disorder, though it is important to know that not every child will develop all of them:

  • Neurodevelopmental disorder: Affecting the growth and development of the brain.
  • Regression: A loss of previously acquired skills or milestones.
  • Abnormal movements: Including issues like dystonia (involuntary muscle contractions) or ataxia (difficulty with balance and coordination) [1][4].
  • Loss of speech: A gradual or sudden decline in the ability to speak or communicate.
  • Seizures: Often beginning after a period of typical development [3].

The condition is considered “ultra-rare” because it has only been identified in a small number of individuals worldwide; one major study included just 32 participants [5]. Because it is so rare, many doctors may never have seen a case before, which is why working with a specialized neurogenetics team is often necessary.

The Genetic Cause: The IRF2BPL Gene

The IRF2BPL gene provides instructions for making a protein that acts as a “transcriptional regulator.” This means it helps control how other genes are turned on or off in the brain [3]. When there is a pathogenic variant (a disease-causing change) in this gene, the protein cannot do its job correctly, leading to the symptoms of NEDAMSS.

In most cases, these genetic changes are de novo, meaning they happened spontaneously in the child and were not inherited from either parent [3][6]. NEDAMSS follows an autosomal dominant inheritance pattern. Even when a variant appears to be de novo, there is a small chance of recurrence in future pregnancies due to germline mosaicism (where the variant is present only in a parent’s egg or sperm cells). There are also rare instances where a variant is inherited from a parent who may show mild or no symptoms at all, a concept known as incomplete penetrance and variable expressivity [7]. Families are strongly encouraged to consult a genetic counselor to discuss recurrence risks and family planning.

The Emotional Journey and Regression

One of the most difficult aspects of NEDAMSS for parents is the timing of the symptoms. Many children with this diagnosis are often reported to have “mostly normal initial psychomotor development” [3]. This means your child may have met their early milestones—like sitting up, crawling, or saying their first words—on time.

The subsequent regression (loss of these skills) often feels like a sudden and devastating shift. This “loss of expectations” can lead to significant grief, yearning, and a sense of helplessness [8]. It is important to know that these feelings are a standard part of the diagnostic experience for families facing medically complex conditions [9].

Clinical Features to Monitor

While the severity and progression of NEDAMSS vary widely from one child to another, the following features are commonly reported:

  • Movement Changes: You may notice hypotonia (low muscle tone/floppiness) or spasticity (muscle stiffness) [10][4].
  • Epilepsy: Seizures can take many forms and may require different types of medication to manage [3][10].
  • Developmental Course: Some children have delays from birth, while others only show signs in later childhood or even adolescence [3][11].

Because the condition is progressive, your medical team will likely focus on supportive, individualized care, such as physical therapy, communication aids, and seizure management, to maintain your child’s comfort and quality of life.

Common questions in this guide

What does a NEDAMSS diagnosis mean for my child?
NEDAMSS is an ultra-rare genetic condition caused by a disease-causing variant in the IRF2BPL gene. It can affect development and may lead to loss of skills or speech, abnormal movements, and seizures, although children do not all have the same features.
Why did my child develop NEDAMSS if neither parent has it?
Most IRF2BPL variants linked to NEDAMSS arise de novo, meaning they occur spontaneously in the child. Rarely, a variant is inherited from a parent with few or no symptoms, so a genetic counselor can explain recurrence risk and family-planning options.
Can a child with NEDAMSS develop typically before symptoms begin?
Yes. Many children have mostly typical early development and later lose skills such as speech, movement abilities, or other milestones. Other children have developmental delays from birth, and the timing and progression vary.
What symptoms should parents watch for with NEDAMSS?
Changes may include loss of developmental skills or speech, seizures, balance or coordination problems, dystonia, low muscle tone, or muscle stiffness. Symptoms and their severity differ from child to child, so new or worsening changes should be discussed with the medical team.
What specialists and tests may be part of NEDAMSS care?
A child may benefit from care involving pediatric neurology, a neurogenetics team, and a genetic counselor. Depending on symptoms and development, the medical team may recommend monitoring or tests such as an EEG or MRI.
How is NEDAMSS treated?
Care is supportive and tailored to the child’s needs rather than based on one standard treatment. It may include physical, occupational, and speech therapy, communication aids, and seizure management to support comfort, function, and quality of life.

Get notified when new evidence is published on IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    IRF2BPL-Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent with DRPLA.

    Venkateswaran S, Michaud J, Ito Y, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(11)):2102-2109 doi:10.1002/mds.29938.

    PMID: 39224955
  2. 2

    Proband only exome sequencing in 403 Indian children with neurodevelopmental disorders: Diagnostic yield, utility and challenges in a resource-limited setting.

    Pranav Chand R, Vinit W, Vaidya V, et al.

    European journal of medical genetics 2023; (66(5)):104730 doi:10.1016/j.ejmg.2023.104730.

    PMID: 36801247
  3. 3

    De novo truncating variants in the intronless IRF2BPL are responsible for developmental epileptic encephalopathy.

    Tran Mau-Them F, Guibaud L, Duplomb L, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(4)):1008-1014 doi:10.1038/s41436-018-0143-0.

    PMID: 30166628
  4. 4

    Novel human neurodevelopmental and neurodegenerative disease associated with IRF2BPL gene variants-mechanisms and therapeutic avenues.

    Bauersachs D, Bomholtz L, Del Rey Mateos S, et al.

    Frontiers in neuroscience 2024; (18()):1426177 doi:10.3389/fnins.2024.1426177.

    PMID: 38903604
  5. 5

    Patient and Family Reported Clinical Picture of IRF2BPL-Related Disorders.

    Goldstone-Joubert Z, Pascual DM, Bailey LA, et al.

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2026; doi:10.1002/ajmg.b.70032.

    PMID: 42629971
  6. 6

    De novo variants of IRF2BPL result in developmental epileptic disorder.

    Wang Y, Ke Z, Li Y, et al.

    Orphanet journal of rare diseases 2024; (19(1)):121 doi:10.1186/s13023-024-03130-z.

    PMID: 38481258
  7. 7

    IRF2BPL Causes Mild Intellectual Disability Followed by Late-Onset Ataxia.

    Heide S, Davoine CS, Cunha P, et al.

    Neurology. Genetics 2023; (9(6)):e200096 doi:10.1212/NXG.0000000000200096.

    PMID: 38235039
  8. 8

    The Rare Life: Examining Parents' Grief, Barriers, and Facilitators Associated with Caring for Medically Complex Children.

    Burke TJ, DeGroot JM, Farris KL, Mellow AJ

    Health communication 2025; (40(1)):36-46 doi:10.1080/10410236.2024.2330130.

    PMID: 38501254
  9. 9

    Psychological Distress among Caregivers of Children with Neurodevelopmental Disorders in Nepal.

    Maridal HK, Bjørgaas HM, Hagen K, et al.

    International journal of environmental research and public health 2021; (18(5)) doi:10.3390/ijerph18052460.

    PMID: 33801567
  10. 10

    Recurrent IRF2BPL c.2152del Variant in NEDAMSS: A Case Report and Comparative Analysis.

    von Quednow E, Bragado López S, Martínez González M, Carrascosa-Romero MC

    American journal of medical genetics. Part A 2026; (200(7)):1702-1709 doi:10.1002/ajmg.a.70113.

    PMID: 41813602
  11. 11

    IRF2BPL as a novel causative gene for progressive myoclonus epilepsy.

    Gardella E, Michelucci R, Christensen HM, et al.

    Epilepsia 2023; (64(8)):e170-e176 doi:10.1111/epi.17634.

    PMID: 37114479

This page explains a child’s NEDAMSS diagnosis for educational purposes and does not replace medical advice. A pediatric neurologist, neurogenetics team, and genetic counselor can interpret your child’s results and recommend individualized monitoring and care.